Dyslipidemia in Renal Transplant Recipients Treated With Cyclosporine A

Niemczyk, Mariusz

doi:10.5812/numonthly.14167

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Calcineurin inhibitors (CNI), including Tac and cyclosporine A, are associated with glucose and lipid metabolism dysregulation [ 57 ]. Tac-related insulin resistance and hyperglycemia correlated with poor prognosis for solid organ recipients [ 58 , 59 ].…”

Section: Resultsmentioning

confidence: 99%

Helper T Cell (CD4⁺) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

et al. 2022

View full text Add to dashboard Cite

Antibody-mediated rejection (ABMR) is a major cause of dysfunction and loss of transplanted kidney. The current treatments for ABMR involve nonspecific inhibition and clearance of T/B cells or plasma cells. However, the prognosis of patients following current treatment is poor. T follicular helper cells (Tfh) play an important role in allograft-specific antibodies secreting plasma cell (PC) development. Tfh cells are therefore considered to be important therapeutic targets for the treatment of antibody hypersecretion disorders, such as transplant rejection and autoimmune diseases. Tacrolimus (Tac), the primary immunosuppressant, prevents rejection by reducing T cell activation. However, its administration should be closely monitored to avoid serious side effects. In this study, we investigated whether Tac delivery to helper T (CD4+) cells using functionalized mesoporous nanoparticles can block Tfh cell differentiation after alloantigen exposure. Results showed that Tac delivery ameliorated humoral rejection injury in rodent kidney graft by suppressing Tfh cell development, PC, and donor-specific antibody (DSA) generation without causing severe side effects compared with delivery through the drug administration pathway. This study provides a promising therapeutic strategy for preventing humoral rejection in solid organ transplantation. The specific and controllable drug delivery avoids multiple disorder risks and side effects observed in currently used clinical approaches.

show abstract

Section: Resultsmentioning

confidence: 99%

Helper T Cell (CD4⁺) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

et al. 2022

View full text Add to dashboard Cite

show abstract

Post-Transplant Cholesterol and Triglyceride Behavior: Effects of Sex, Age of the Recipient, and Type of Donor

Rodriguez

Santiago

Jiménez

et al. 2020

Transplantation Proceedings

View full text Add to dashboard Cite

Dyslipidemia in Renal Transplant Recipients Treated With Cyclosporine A

Cited by 2 publications

References 5 publications

Helper T Cell (CD4⁺) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Helper T Cell (CD4⁺) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Post-Transplant Cholesterol and Triglyceride Behavior: Effects of Sex, Age of the Recipient, and Type of Donor

Contact Info

Product

Resources

About

Dyslipidemia in Renal Transplant Recipients Treated With Cyclosporine A

Cited by 2 publications

References 5 publications

Helper T Cell (CD4+) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Helper T Cell (CD4+) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Post-Transplant Cholesterol and Triglyceride Behavior: Effects of Sex, Age of the Recipient, and Type of Donor

Contact Info

Product

Resources

About

Helper T Cell (CD4⁺) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Helper T Cell (CD4⁺) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity